Parkinson’s Disease: Approval Of Disease Modifying Therapies Will Be Key To Better Treatment Outcomes
Pharmaceuticals / United States / Mon 18 Mar, 2024
Key View
- A lack of current effective treatment is driving research into disease modifying therapies (DMTs) for Parkinson’s disease (PD).
- We expect Alpha Synuclein (ASN) Inhibitors will be the first form of DMT for PD to receive FDA approval.
- Drugs which engage neuronal rescue pathways, like GLP-1 agonists, have also shown promise in the